Implantica (IMP) Q3 2025 earnings summary

Executive summary

• Significant progress toward U.S. FDA approval for RefluxStop, with successful inspections, regulatory milestones, and positive FDA feedback.

• RefluxStop addresses a large unmet need in acid reflux treatment, offering superior outcomes and fewer side effects compared to existing solutions.

• NICE in the U.K. has approved RefluxStop for NHS public hospitals and severe GERD cases, expanding market potential.

• U.S. market launch preparations are underway, including production scaling, new tools, and engagement with key opinion leaders.

• RefluxStop generated significant enthusiasm at major U.S. conferences, reinforcing clinical credibility.

Financial highlights

• Q3 net sales reached EUR 365,000, up 6% year-over-year; nine-month net sales were EUR 1,543,000, up 3%.

• Adjusted gross margin was 93% in Q3 (down from 97%); nine-month margin improved to 94%.

• Q3 operating loss was EUR 4.4 million, a 17% year-over-year decrease; nine-month EBIT loss reduced to EUR 13.13 million.

• Net loss for Q3 was EUR 4.415 million; nine-month net loss was EUR 12.627 million.

• Cash and short-term investments totaled EUR 53.3 million at quarter-end.

Outlook and guidance

• Best estimate for U.S. FDA approval is the second half of Q1, with a well-defined path to U.S. market entry.

• U.S. hospital contracts expected to take at least three months post-approval before surgeries can begin.

• Expansion in the U.K. anticipated following NICE recommendation; regulatory submissions for Japan, Canada, and Brazil planned for 2026.

• R&D and new product launches are on hold until after U.S. launch.